Morgan Stanley initiated coverage of Roche (RHHBY) with an Equal Weight rating and CHF 305 price target The firm sees the end of Roche’s earnings downgrade cycle, with a pick up in “high risk / high reward” pipeline catalysts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Balanced Outlook on Roche Holding Amid Gazyva’s Promising Yet Uncertain Prospects
- Recursion Pharmaceuticals’ (RXRX) AI Approach to Drug Discovery Shows Progress
- Trump Trade: President advocates to close carried interest tax loophole
- Genentech publishes REGENCY trial data in the New England Journal of Medicine
- White House readying order to fire thousands of federal health workers, WSJ says